ClinicalTrials.gg
RecruitingNCT07376577Anricofen CiprUpdated Nov 9, 2026

Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCP

An interventional study of Sufentanil and Anricofen in Anesthesia and Endoscopic Retrograde Cholangiopancreatography (ERCP), sponsored by The First Affiliated Hospital of Xinxiang Medical College. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by The First Affiliated Hospital of Xinxiang Medical College · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 9, 2026Enrollment updatedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to compare postoperative recovery quality and safety between anricofen combined with ciprofol and sufentanil combined with ciprofol in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) under non-intubated anesthesia.

This is a single-center, prospective, randomized, controlled study involving patients aged 18-80 years who are scheduled for elective ERCP. A total of 180 participants are planned to be enrolled and randomly assigned in a 1:1 ratio to two groups.

Participants in the anricofen group will receive intravenous anricofen (HSK21542) at a dose of 1 μg/kg before ciprofol induction. Participants in the sufentanil group will receive intravenous sufentanil at a dose of 0.1 μg/kg before ciprofol induction. Both groups will receive ciprofol for anesthesia induction and maintenance.

The primary outcome is the total Quality of Recovery-15 (QoR-15) score at 24 hours after the procedure. Secondary outcomes include postoperative pain scores at different time points, total ciprofol consumption, recovery time, post-anesthesia care unit stay, respiratory and hemodynamic adverse events, postoperative nausea and vomiting, and serious adverse events.

The study is expected to provide clinical evidence on the postoperative recovery quality and safety of these two analgesic regimens for patients undergoing ERCP under non-intubated anesthesia.

02

Conditions studied

  • Anesthesia
  • Endoscopic Retrograde Cholangiopancreatography (ERCP)
03

In context

Lead sponsor

The First Affiliated Hospital of Xinxiang Medical College is the lead sponsor of 42 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

**Inclusion Criteria:**

  1. Aged 18 to 80 years;
  2. (ASA) physical status I to III;
  3. Patients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP).

**Exclusion Criteria:**

  1. Pregnancy or lactation;
  2. Obstructive sleep apnea (OSA);
  3. Long-term use of analgesics or psychotropic drugs, or a history of drug abuse;
  4. Coagulation dysfunction, bleeding tendency, or current anticoagulant therapy;
  5. Allergy to any of the study drugs;
  6. Severe cardiac, hepatic, renal, or other major organ diseases;
  7. Mental or cognitive impairment that prevents cooperation with the assessment;
  8. Inability to comply with the study protocol or complete follow-up;
  9. Requirement for tracheal intubation, postoperative transfer to the intensive care unit (ICU), or postoperative pancreatitis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Anricofen(HSK21542) 1 μg/kg + Ciprofol

    Drug: Anricofen · Drug: Ciprofol

  • Active comparator
    Sufentanil 0.1 μg/kg + Ciprofol

    Drug: Sufentanil · Drug: Ciprofol

Interventions

  • Sufentanil is an opioid analgesic. In this study, it is used as the active comparator and administered intravenously at a dose of 0.1 μg/kg 3 minutes before ciprofol induction by slow injection.

  • DrugAnricofen

    Anricofen (HSK21542) is a peripherally restricted κ-opioid receptor agonist. In this study, it is administered intravenously at a dose of 1 μg/kg 3 minutes before ciprofol induction by slow injection.

  • Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses.

06

What researchers measure

Primary outcomes

  1. Quality of Recovery-15 (QoR-15) Score at 24 Hours Postoperatively

    The primary outcome is the total score of the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours after ERCP. The QoR-15 is a patient-reported measure of postoperative recovery quality, with total scores ranging from 0 to 150. Higher scores indicate better postoperative recovery quality.

    Time frame: 24 hours after the procedure

Secondary outcomes

  1. Resting Numerical Rating Scale (NRS) Pain Score

    Resting pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), at the prespecified postoperative assessment time points.

    Time frame: At prespecified time points postoperatively

  2. Total Ciprofol Consumption

    The total dose of ciprofol administered to each participant during the ERCP procedure will be recorded and compared between the two groups.

    Time frame: During the ERCP procedure

  3. Respiratory and Hemodynamic Adverse Events

    The incidence and details of perioperative respiratory and hemodynamic adverse events will be recorded. Respiratory events include hypoxemia, apnea or significant hypoventilation, airway interventions, mask-assisted ventilation, supraglottic airway placement, and emergency tracheal intubation. Hemodynamic events include hypotension, bradycardia, and the use of vasoactive drugs such as norepinephrine or atropine.

    Time frame: During the procedure and up to 24 hours postoperatively

  4. Postoperative Nausea and Vomiting (PONV)

    The occurrence of postoperative nausea and vomiting will be recorded and compared between the two groups.

    Time frame: Within 24 hours postoperatively

  5. Serious Adverse Events (SAEs)

    The occurrence, type, and details of serious adverse events will be recorded throughout the study period.

    Time frame: From enrollment until the end of the study

  6. Recovery Time

    The time required for participants to recover from anesthesia after the ERCP procedure will be recorded and compared between the two groups.

    Time frame: From the end of the ERCP procedure to recovery

  7. Post-Anesthesia Care Unit (PACU) Length of Stay

    The duration of stay in the post-anesthesia care unit (PACU) after the procedure will be recorded and compared between the two groups.

    Time frame: From PACU admission to PACU discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 29, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Mar 2028
CompletionEst.
May 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
141→180
Nov 9, 2026
Eligibility
Minimum age 60 Years→18 Years; Maximum age 90 Years→80 Years; Criteria largely rewritten (30 changes)
What changed in the criteria
  • Removed-
  • RemovedInclusion Criteria:
  • RemovedAge 60-90 years.
  • AddedAged 18 to 80 years;
  • EditedAmerican Society of Anesthesiologists (ASA) physical status II orI to III.;
  • EditedScheduled forPatients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP).
  • RemovedBody mass index (BMI) between 18 and 30 kg/m².
  • RemovedWilling and able to provide written informed consent.
  • RemovedSevere neurological disorders (acute stroke, uncontrolled seizures, epilepsy).
  • RemovedPsychiatric disorders or cognitive impairment (Mini-Mental State Examination score <24).
  • RemovedUncontrolled hypertension (preoperative blood pressure ≥180/110 mmHg) or hypotension (<90/60 mmHg).
  • RemovedSevere cardiac disease: sinus bradycardia, sick sinus syndrome, unstable angina, or myocardial infarction within the past 3 months.
  • RemovedSevere hepatic or renal dysfunction.
  • RemovedDifficult airway or severe respiratory disease.
  • RemovedAchalasia.
  • RemovedKnown allergy to anricofen, sufentanil, ciprofol, or other study medications.
  • RemovedUse of opioid analgesics or sedatives within 7 days prior to surgery.
  • RemovedPreoperative pulse oxygen saturation (SpO₂) <90% on room air.
  • RemovedParticipation in any other drug clinical trial within the past 3 months.
  • RemovedRefusal to participate in the study.
  • RemovedExclusion Criteria:
  • Removed-
  • AddedObstructive sleep apnea (OSA);
  • AddedLong-term use of analgesics or psychotropic drugs, or a history of drug abuse;
  • AddedCoagulation dysfunction, bleeding tendency, or current anticoagulant therapy;
  • AddedAllergy to any of the study drugs;
  • AddedSevere cardiac, hepatic, renal, or other major organ diseases;
  • AddedMental or cognitive impairment that prevents cooperation with the assessment;
  • AddedInability to comply with the study protocol or complete follow-up;
  • AddedRequirement for tracheal intubation, postoperative transfer to the intensive care unit (ICU), or postoperative pancreatitis.
Nov 9, 2026
Interventions
Arm changed Sufentanil 0.1 μg/kg + Ciprofol 1.0 mg/kg→Sufentanil 0.1 μg/kg + Ciprofol. Arms added: Anricofen(HSK21542) 1 μg/kg + Ciprofol; arms removed: Anricofen 0.3 μg/kg + Ciprofol 1.0 mg/kg·Anricofen 0.5 μg/kg + Ciprofol 1.0 mg/kg
Nov 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Intraoperative Pain Control Success RateNow Quality of Recovery-15 (QoR-15) Score at 24 Hours PostoperativelyTime frame: During the ERCP procedure (from induction to end of procedure) → 24 hours after the procedure
Nov 9, 2026
Secondary outcomes
7 added
What changed in the outcomes
  • AddedResting Numerical Rating Scale (NRS) Pain ScoreTime frame: At prespecified time points postoperatively
  • AddedTotal Ciprofol ConsumptionTime frame: During the ERCP procedure
  • AddedRespiratory and Hemodynamic Adverse EventsTime frame: During the procedure and up to 24 hours postoperatively
  • AddedPostoperative Nausea and Vomiting (PONV)Time frame: Within 24 hours postoperatively
  • AddedSerious Adverse Events (SAEs)Time frame: From enrollment until the end of the study
  • AddedRecovery TimeTime frame: From the end of the ERCP procedure to recovery
  • AddedPost-Anesthesia Care Unit (PACU) Length of StayTime frame: From PACU admission to PACU discharge
Nov 9, 2026
Title
Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing ERCP→Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCP
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Enrollment 141→180
    Eligibility Minimum age 60 Years→18 Years; Maximum age 90 Years→80 Years; Criteria largely rewritten (30 changes)
    What changed in the criteria
    • Removed-
    • RemovedInclusion Criteria:
    • RemovedAge 60-90 years.
    • AddedAged 18 to 80 years;
    • EditedAmerican Society of Anesthesiologists (ASA) physical status II orI to III.;
    • EditedScheduled forPatients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP).
    • RemovedBody mass index (BMI) between 18 and 30 kg/m².
    • RemovedWilling and able to provide written informed consent.
    • RemovedSevere neurological disorders (acute stroke, uncontrolled seizures, epilepsy).
    • RemovedPsychiatric disorders or cognitive impairment (Mini-Mental State Examination score <24).
    • RemovedUncontrolled hypertension (preoperative blood pressure ≥180/110 mmHg) or hypotension (<90/60 mmHg).
    • RemovedSevere cardiac disease: sinus bradycardia, sick sinus syndrome, unstable angina, or myocardial infarction within the past 3 months.
    • RemovedSevere hepatic or renal dysfunction.
    • RemovedDifficult airway or severe respiratory disease.
    • RemovedAchalasia.
    • RemovedKnown allergy to anricofen, sufentanil, ciprofol, or other study medications.
    • RemovedUse of opioid analgesics or sedatives within 7 days prior to surgery.
    • RemovedPreoperative pulse oxygen saturation (SpO₂) <90% on room air.
    • RemovedParticipation in any other drug clinical trial within the past 3 months.
    • RemovedRefusal to participate in the study.
    • RemovedExclusion Criteria:
    • Removed-
    • AddedObstructive sleep apnea (OSA);
    • AddedLong-term use of analgesics or psychotropic drugs, or a history of drug abuse;
    • AddedCoagulation dysfunction, bleeding tendency, or current anticoagulant therapy;
    • AddedAllergy to any of the study drugs;
    • AddedSevere cardiac, hepatic, renal, or other major organ diseases;
    • AddedMental or cognitive impairment that prevents cooperation with the assessment;
    • AddedInability to comply with the study protocol or complete follow-up;
    • AddedRequirement for tracheal intubation, postoperative transfer to the intensive care unit (ICU), or postoperative pancreatitis.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Intraoperative Pain Control Success RateNow Quality of Recovery-15 (QoR-15) Score at 24 Hours PostoperativelyTime frame: During the ERCP procedure (from induction to end of procedure) → 24 hours after the procedure
    Secondary outcomes 7 added
    What changed in the outcomes
    • AddedResting Numerical Rating Scale (NRS) Pain ScoreTime frame: At prespecified time points postoperatively
    • AddedTotal Ciprofol ConsumptionTime frame: During the ERCP procedure
    • AddedRespiratory and Hemodynamic Adverse EventsTime frame: During the procedure and up to 24 hours postoperatively
    • AddedPostoperative Nausea and Vomiting (PONV)Time frame: Within 24 hours postoperatively
    • AddedSerious Adverse Events (SAEs)Time frame: From enrollment until the end of the study
    • AddedRecovery TimeTime frame: From the end of the ERCP procedure to recovery
    • AddedPost-Anesthesia Care Unit (PACU) Length of StayTime frame: From PACU admission to PACU discharge
    Interventions Arm changed Sufentanil 0.1 μg/kg + Ciprofol 1.0 mg/kg→Sufentanil 0.1 μg/kg + Ciprofol. Arms added: Anricofen(HSK21542) 1 μg/kg + Ciprofol; arms removed: Anricofen 0.3 μg/kg + Ciprofol 1.0 mg/kg·Anricofen 0.5 μg/kg + Ciprofol 1.0 mg/kg
    Title Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing ERCP→Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCP
    + 4 other changes: date precision, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07376577
Lead sponsor
The First Affiliated Hospital of Xinxiang Medical College
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Jan 1, 2026
Primary completion
Mar 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Longhua Guo
Contact
1535732839@qq.com
18303733012

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion